SCHEMBL5135859

SCHEMBL5135859

O=C(c1ccccc1-n1ccnc1)N(Cc1ccccc1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
HPGD P15428 5/20 0.55
MAPT P10636 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
KMT2A Q03164 2/20 0.47
USP2 O75604 2/20 0.46
MAPK1 P28482 2/20 0.46
TSHR P16473 4/20 0.45
TDP1 Q9NUW8 1/20 0.45
TAS2R14 Q9NYV8 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
PTPN1 P18031 1/20 0.43
NOS2 P35228 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766609 0.83 ALDH1A1 (0.56) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL5137552 0.81 ALDH1A1 (0.52) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL14099478 0.78 ALDH1A1 (0.64) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL5134630 0.77 ALDH1A1 (0.62) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL5137118 0.75 ALDH1A1 (0.47) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL5136876 0.74 ALDH1A1 (0.59) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL5136192 0.74 ALDH1A1 (0.50) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL5136157 0.72 TSHR (0.59) ALDH1A1MAPTSMN1; SMN2KMT2AMAPK1
SCHEMBL4766559 0.71 ALDH1A1 (0.55) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1
SCHEMBL6987023 0.70 USP2 (0.49) ALDH1A1HPGDMAPTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed